Last reviewed · How we verify
Anti-platelet therapy
Anti-platelet therapy inhibits platelet aggregation to prevent blood clots and reduce thrombotic events.
Anti-platelet therapy inhibits platelet aggregation to prevent blood clots and reduce thrombotic events. Used for Acute coronary syndrome, Stroke prevention, Peripheral arterial disease.
At a glance
| Generic name | Anti-platelet therapy |
|---|---|
| Sponsor | Boston Scientific Corporation |
| Drug class | Anti-platelet agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Anti-platelet agents work by interfering with platelet activation and adhesion through various mechanisms, such as inhibiting cyclooxygenase (aspirin), blocking ADP receptors (P2Y12 inhibitors), or inhibiting phosphodiesterase. By reducing platelet clumping, these drugs decrease the risk of thrombotic complications in cardiovascular and cerebrovascular conditions.
Approved indications
- Acute coronary syndrome
- Stroke prevention
- Peripheral arterial disease
- Post-percutaneous coronary intervention
Common side effects
- Bleeding
- Gastrointestinal hemorrhage
- Dyspepsia
- Bruising
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Niraparib in Patients With Pancreatic Cancer (PHASE2)
- Monitoring of Anti-TFPI in Hemophilia
- Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding (NA)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-platelet therapy CI brief — competitive landscape report
- Anti-platelet therapy updates RSS · CI watch RSS
- Boston Scientific Corporation portfolio CI